About Pipeline Science Contact

Advancing Cell Therapies
to Transform
Solid Tumor Care

Scroll

About

Bridging biotech
from bench to bedside.

PhryctaBio is a clinical-stage biotechnology company focused on developing transformative immune cell therapies for solid tumors. We have built a diversified pipeline to address significant unmet needs, tackling key barriers in solid tumor immunotherapy, including immune resistance, antigen heterogeneity, and post-ablation recurrence.

2025
Founded
4
Pipeline Programs
3
R&D LocationsHarbin · Beijing · Suzhou
IIT
PHR001 in Clinical Stage

Pipeline

Diversified portfolio addressing key barriers in solid tumor immunotherapy

PHR 001 Autologous Cell Therapy
Solid Tumors (MSI-H CRC)
Discovery
Pre-Clinical
IIT / Clinical
IND-Enabling
PHR 002 CAR-T
CAR-T for Solid Tumors
Discovery
Pre-Clinical
IIT / Clinical
IND-Enabling
PHR 003 In Vivo CAR-T
In Vivo CAR-T for Solid Tumors
Discovery
Pre-Clinical
IIT / Clinical
IND-Enabling
PHR 004 Drug Delivery
Cell-Based Drug Delivery
Discovery
Pre-Clinical
IIT / Clinical
IND-Enabling

Science

Foundational research published in top-tier journals

Our programs are built on rigorous, peer-reviewed science with publications in leading journals that validate our therapeutic approach.

Nature Cell Biology
2025
PHR001

CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8⁺ T cell exhaustion in colorectal cancer

  • Identified CD160⁺ CD8⁺ T cells as key anti-tumor immune subset
  • Demonstrated CD160 activates PI3K-AKT-NF-κB signaling pathway
  • CD160⁺ T cell adoptive therapy overcomes anti-PD-1 resistance in MSI-H CRC
  • Peer-reviewed commentary by Prof. Ping-Chih Ho (Ludwig Cancer Research)
Nature Biomedical Engineering
2025
PHR002 / PHR003

Engineered outer membrane vesicles enhances solid tumor CAR-T cell therapy

  • POMV demonstrates superior tumor targeting and PD-L1 blockade
  • BROAD-CAR platform achieves curative efficacy in heterogeneous tumor models
  • Induces durable anti-tumor immune memory upon tumor rechallenge
  • Effective across breast, lung metastasis, and orthotopic liver cancer models
Hepatology
2024
PHR004

Macrophage hitchhiking for systematic suppression in postablative multifocal HCC

  • Designed drug-loaded macrophages leveraging post-ablation inflammation gradient
  • Achieved ~10× increase in drug concentration at residual tumor sites
  • Demonstrated significant efficacy in mouse and large-animal HCC models

Contact

We invite inquiries regarding clinical collaborations, strategic partnerships, and investment opportunities.

Email info@phryctabio.com
Locations Harbin · Beijing · Suzhou